Skip to main content
AstraZenecaPatent grant

AstraZeneca was granted a patent for CDK2-targeting drug compounds.

Source: Autobound Signal API · 84 signals tracked for AstraZeneca · updated

Get AstraZeneca's live signals in Claude or ChatGPT, or by API

AskWhat changed at AstraZeneca this week? Use Autobound signals for astrazeneca.com.

What happened

In November 2026 AstraZeneca patented purine-based medicines intended to treat or prevent CDK2-related conditions, for use in pharmaceutical treatment and research.

Source

patents.google.comNov 10, 2026

US patent US12790352

2,6,9-trisubstituted purines

Abstract

Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein R 1, R 2, R 3, R 4, and R 5 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent cyclin-dependent kinase 2 (CDK2)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.

patents.google.com/patent/US12790352Read the full source

Extracted by Autobound

From the Signal API record
Signal
Patent grant

What this signalsA new patent often shows where a company is putting its R&D budget.

Grant date
Nov 10, 2026
Inventors
4
Patent number
US12790352
Assignee
AstraZeneca AB

The full record

From the Signal API record

People

  • Bernard BarlaamInventor
  • Michael BodnarchukInventor
  • Avipsa GhoshInventor
  • Frederick GoldbergInventor
  • Sudhir HandeInventor
  • Phillip LichtorInventor

Details

Primary CPC class
C07D 519/00
USPTO assignee
AstraZeneca AB
What the invention does
A family of chemical compounds designed to block CDK2, a protein involved in conditions that may respond to its inhibition.

Topics and mentions

Tags

  • Intellectual Property
  • Research & Development
  • Pharmaceuticals
  • Medical Research

Technologies named

  • medicinal chemistry
  • CDK2 inhibitors
  • pharmaceutical compounds

Extraction

Detected
Nov 11, 2026
signal_type
patents-company
signal_subtype
patentGrant

Use this data

Get every patent signal for AstraZeneca and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at AstraZeneca this week?”

  2. Send it to your own tools

    The Signal API returns patent signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full patents-company record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/01d52edb-8b15-522a-ad9d-6989c58013df returns this record as JSON. POST /v1/companies/enrich returns every signal for astrazeneca.com.

{
  "signal_id": "01d52edb-8b15-522a-ad9d-6989c58013df",
  "signal_type": "patents-company",
  "signal_subtype": "patentGrant",
  "detected_at": "2026-11-11T15:21:31+00:00",
  "company": {
    "name": "AstraZeneca",
    "domain": "astrazeneca.com"
  },
  "data": {
    "cpc": [
      {
        "code": "C07D 519/00"
      },
      {
        "code": "A61K 31/52"
      },
      {
        "code": "A61P 31/00"
      },
      {
        "code": "C07D 487/04"
      }
    ],
    "tags": [
      "Intellectual Property",
      "Research & Development",
      "Pharmaceuticals",
      "Medical Research"
    ],
    "detail": "In November 2026 AstraZeneca patented purine-based medicines intended to treat or prevent CDK2-related conditions, for use in pharmaceutical treatment and research.",
    "summary": "AstraZeneca was granted a patent for CDK2-targeting drug compounds.",
    "event_at": "2026-11-10",
    "inventors": [
      {
        "name": "Bernard Barlaam",
        "status": "resolved",
        "is_primary": true,
        "linkedin_url": "https://www.linkedin.com/in/bernard-barlaam-216aba3b"
      },
      {
        "name": "Michael Bodnarchuk",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/michael-bodnarchuk-9618ab63"
      },
      {
        "name": "Avipsa Ghosh",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/avipsa-ghosh-7592053a"
      },
      {
        "name": "Frederick Goldberg",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/frederick-goldberg-05226111"
      },
      {
        "name": "Sudhir Hande",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/sudhir-hande-5088ab49"
      },
      {
        "name": "Phillip Lichtor",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/phillip-lichtor-86796613"
      },
      {
        "name": "Kun Song",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/kunsong"
      },
      {
        "name": "Qibin Su",
        "status": "unresolved",
        "is_primary": false
      }
    ],
    "event_kind": "grant_date",
    "grant_date": "2026-11-10",
    "source_url": "https://patents.google.com/patent/US12790352",
    "cpc_primary": {
      "code": "C07D 519/00"
    },
    "patent_title": "2,6,9-trisubstituted purines",
    "patent_number": "US12790352",
    "uspto_assignee": "AstraZeneca AB",
    "patent_abstract": "Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 , and R 5 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent cyclin-dependent kinase 2 (CDK2)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.",
    "precision_class": "structural",
    "invention_explanation": "A family of chemical compounds designed to block CDK2, a protein involved in conditions that may respond to its inhibition.",
    "technologies_mentioned": [
      "medicinal chemistry",
      "CDK2 inhibitors",
      "pharmaceutical compounds"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.